Premium
Oncogene alterations in primary, recurrent, and metastatic human bone tumors
Author(s) -
Pompetti Franca,
Rizzo Paola,
Simon Richard M.,
Freidlin Boris,
Mew Daphne J.,
Pass Harvey I.,
Picci Piero,
Levine Arthur S.,
Carbone Michele
Publication year - 1996
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/(sici)1097-4644(199610)63:1<37::aid-jcb3>3.0.co;2-0
Subject(s) - osteosarcoma , chondrosarcoma , oncogene , cancer research , suppressor , primary bone , biology , pathology , tumor suppressor gene , gene , gene duplication , medicine , cell cycle , carcinogenesis , genetics
We investigated the structure and the expression of various oncogenes in three of the most common human bone tumors—osteosarcoma (36 samples from 34 patients), giant cell tumor (10 patients), and chondrosarcoma (18 patients)—in an attempt to identify the genetic alterations associated with these malignancies. Alterations of RB and p53 were detected only in osteosarcomas. Alterations of c‐myc, N‐myc, and c‐fos were detected in osteosarcomas and giant cell tumors. Ras alterations (H‐ras, Ki‐ras, N‐ras) were rare. Chondrosarcomas did not contain any detectable genetic alterations. Our results suggest that alterations of c‐myc, N‐myc, and c‐fos oncogenes occur in osteosarcomas, in addition to those previously described for the tumor suppressor genes RB and p53. Moreover, statistical analyses indicate that c‐fos alterations occur more frequently in osteosarcoma patients with recurrent or metastatic disease. © 1996 Wiley‐Liss, Inc.